Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)

The introduction of immunotherapeutic agents has provided renewed hope for Chronic lymphocytic leukemia fludarabine-refractory patients. Several clinical trials have shown that alemtuzumab is a more effective option compared to combination chemotherapy for treatment of patients who have relapsed or...

Descripción completa

Detalles Bibliográficos
Autores principales: Montillo, Marco, Ricci, Francesca, Miqueleiz, Sara, Tedeschi, Alessandra, Morra, Enrica
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727786/
https://www.ncbi.nlm.nih.gov/pubmed/19707426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727786/
https://www.ncbi.nlm.nih.gov/pubmed/19707426

Ejemplares similares